KR20210131370A - Grn-연관 성인-발병 신경퇴화의 치료를 위한 재조합 아데노-연관 바이러스 - Google Patents

Grn-연관 성인-발병 신경퇴화의 치료를 위한 재조합 아데노-연관 바이러스 Download PDF

Info

Publication number
KR20210131370A
KR20210131370A KR1020217029575A KR20217029575A KR20210131370A KR 20210131370 A KR20210131370 A KR 20210131370A KR 1020217029575 A KR1020217029575 A KR 1020217029575A KR 20217029575 A KR20217029575 A KR 20217029575A KR 20210131370 A KR20210131370 A KR 20210131370A
Authority
KR
South Korea
Prior art keywords
gly
pro
ser
ala
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020217029575A
Other languages
English (en)
Korean (ko)
Inventor
크리스티안 힌더러
님로드 밀러
제임스 엠. 윌슨
Original Assignee
더 트러스티스 오브 더 유니버시티 오브 펜실베니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 filed Critical 더 트러스티스 오브 더 유니버시티 오브 펜실베니아
Publication of KR20210131370A publication Critical patent/KR20210131370A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020217029575A 2019-02-22 2020-02-21 Grn-연관 성인-발병 신경퇴화의 치료를 위한 재조합 아데노-연관 바이러스 Pending KR20210131370A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962809329P 2019-02-22 2019-02-22
US62/809,329 2019-02-22
US201962923812P 2019-10-21 2019-10-21
US62/923,812 2019-10-21
US202062969108P 2020-02-02 2020-02-02
US62/969,108 2020-02-02
PCT/US2020/019149 WO2020172490A1 (en) 2019-02-22 2020-02-21 Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration

Publications (1)

Publication Number Publication Date
KR20210131370A true KR20210131370A (ko) 2021-11-02

Family

ID=70058449

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217029575A Pending KR20210131370A (ko) 2019-02-22 2020-02-21 Grn-연관 성인-발병 신경퇴화의 치료를 위한 재조합 아데노-연관 바이러스

Country Status (16)

Country Link
US (1) US12416017B2 (enExample)
EP (1) EP3927381A1 (enExample)
JP (2) JP7637058B2 (enExample)
KR (1) KR20210131370A (enExample)
CN (1) CN113710281A (enExample)
AU (1) AU2020225472A1 (enExample)
BR (1) BR112021015817A2 (enExample)
CA (1) CA3129672A1 (enExample)
CL (1) CL2021002172A1 (enExample)
CO (1) CO2021011040A2 (enExample)
IL (1) IL285654A (enExample)
MX (1) MX2021010134A (enExample)
PE (1) PE20211819A1 (enExample)
SG (1) SG11202108504YA (enExample)
TW (1) TW202045730A (enExample)
WO (1) WO2020172490A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022523913A (ja) * 2019-02-01 2022-04-27 アブロバイオ，インコーポレーテッド 神経認知障害を処置するための組成物及び方法
SG11202108504YA (en) 2019-02-22 2021-09-29 Univ Pennsylvania Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
GB201913974D0 (en) * 2019-09-27 2019-11-13 King S College London Vector
CN115715327A (zh) * 2019-10-22 2023-02-24 应用遗传科技公司 用于治疗颗粒蛋白前体相关的神经退行性疾病或病症的腺伴随病毒(aav)系统
EP4204014A1 (en) * 2020-08-26 2023-07-05 The Trustees of The University of Pennsylvania Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
WO2022131322A1 (ja) * 2020-12-17 2022-06-23 国立大学法人京都大学 神経細胞賦活剤
EP4473123A2 (en) * 2022-02-01 2024-12-11 Shape Therapeutics Inc. Stable cell lines for inducible production of raav virions
WO2024245120A1 (en) * 2023-05-26 2024-12-05 Shanghai Vitalgen Biopharma Co., Ltd. Recombinant aav vectors for treating proteinopathies in central nervous system
AU2024311750A1 (en) * 2023-06-21 2025-12-18 Eli Lilly And Company Compounds for the delivery of granulin across the blood brain barrier
WO2025188625A1 (en) * 2024-03-03 2025-09-12 Passage Bio, Inc. Recombinant adeno-associated virus for treatment of neurodegenerative disorders

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
CA2287478C (en) 1997-04-14 2007-06-19 Richard J. Samulski Methods for increasing the efficiency of recombinant aav product
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
US6759237B1 (en) 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
AU768729B2 (en) 1998-11-05 2004-01-08 Trustees Of The University Of Pennsylvania, The Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
US6491907B1 (en) 1998-11-10 2002-12-10 The University Of North Carolina At Chapel Hill Recombinant parvovirus vectors and method of making
AU2001268149B2 (en) 2000-06-01 2005-08-18 University Of North Carolina At Chapel Hill Methods and compounds for controlled release of recombinant parvovirus vectors
ATE317916T1 (de) 2001-11-13 2006-03-15 Univ Pennsylvania Verfahren zur identifizierung von adeno- assoziiertem virus (aav) sequenzen sowie kit zur ausführung der methode
US20070015238A1 (en) 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
ES2874298T3 (es) 2003-09-30 2021-11-04 Univ Pennsylvania Clados de virus adenoasociados (AAV), secuencias, vectores que contienen el mismo, y usos de los mismos
ES2428218T3 (es) 2005-04-07 2013-11-06 The Trustees Of The University Of Pennsylvania Cápsides de AAV rh48 modificadas, composiciones que las contienen y usos de las mismas
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
DK2687223T4 (da) 2006-05-30 2025-02-17 Mayo Found Medical Education & Res Påvisning og behandling af demens
CA2654292C (en) 2006-06-07 2022-01-11 Genzyme Corporation Gene therapy for motor neuron disorders
EP3009143B1 (en) 2008-01-16 2018-10-03 Neurodyn Life Sciences Inc. Progranulin for use in treating parkinson's disease or alzheimer's disease
HUE072183T2 (hu) 2009-05-02 2025-10-28 Genzyme Corp Génterápia neurodegeneratív betegségekre
US20110203007A1 (en) 2010-02-16 2011-08-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Assays of neurodegenerative disorders, including frontotemporal dementia and amyotrophic lateral sclerosis
US20130023033A1 (en) 2010-03-29 2013-01-24 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
JP6312436B2 (ja) 2010-11-16 2018-04-18 ニューロダイン ライフ サイエンシズ インコーポレイテッドＮｅｕｒｏｄｙｎ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． ネプリライシンの発現および活性を増大させるための方法および医薬組成物
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
US10780182B2 (en) * 2014-04-25 2020-09-22 The Trustees Of The University Of Pennsylvania Methods and compositions for treating metastatic breast cancer and other cancers in the brain
SG11201706445SA (en) * 2015-02-10 2017-09-28 Genzyme Corp Enhanced delivery of viral particles to the striatum and cortex
MX2018004755A (es) * 2015-10-29 2018-12-19 Voyager Therapeutics Inc Entrega de polinucleotidos dirigidos al sistema nervioso central.
US20190060359A1 (en) 2015-11-02 2019-02-28 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
US11098286B2 (en) 2015-12-11 2021-08-24 The Trustees Of The University Of Pennsylvania Scalable purification method for AAV9
EP3992283A1 (en) 2015-12-11 2022-05-04 The Trustees Of The University Of Pennsylvania Scalable purification method for aavrh10
WO2017100674A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav1
EP3387117B1 (en) 2015-12-11 2022-11-23 The Trustees Of The University Of Pennsylvania Scalable purification method for aav8
KR20180121899A (ko) 2016-02-03 2018-11-09 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 I형 점액다당류증을 치료하기 위한 유전자 요법
CA3016314A1 (en) 2016-03-02 2017-09-08 Julianne REIDERS Therapy for frontotemporal dementia
WO2018013775A2 (en) 2016-07-14 2018-01-18 Emory University Granulin compositions and uses related thereto
JP7610923B2 (ja) 2016-09-02 2025-01-09 スパーク セラピューティクス インコーポレイテッド Ｃｎｓ障害を治療するための方法及びベクター
WO2018160582A1 (en) 2017-02-28 2018-09-07 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) clade f vector and uses therefor
KR20200078513A (ko) 2017-10-03 2020-07-01 프리베일 테라퓨틱스, 인크. 리소좀 장애를 위한 유전자 요법
JP7361037B2 (ja) 2017-10-03 2023-10-13 プリベイル セラピューティクス，インコーポレーテッド ライソゾーム病の遺伝子治療
US20200283800A1 (en) 2017-10-23 2020-09-10 Prevail Therapeutics, Inc. Gene therapies for neurodegenerative diseases
JP2022523913A (ja) 2019-02-01 2022-04-27 アブロバイオ，インコーポレーテッド 神経認知障害を処置するための組成物及び方法
SG11202108504YA (en) 2019-02-22 2021-09-29 Univ Pennsylvania Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration
EP4204014A1 (en) 2020-08-26 2023-07-05 The Trustees of The University of Pennsylvania Recombinant adeno-associated virus for treatment of grn-associated adult-onset neurodegeneration

Also Published As

Publication number Publication date
SG11202108504YA (en) 2021-09-29
PE20211819A1 (es) 2021-09-14
MX2021010134A (es) 2021-09-23
BR112021015817A2 (pt) 2021-10-13
IL285654A (en) 2021-09-30
JP2025081439A (ja) 2025-05-27
CO2021011040A2 (es) 2021-09-09
AU2020225472A1 (en) 2021-08-26
US12416017B2 (en) 2025-09-16
US20220136008A1 (en) 2022-05-05
JP2022523766A (ja) 2022-04-26
TW202045730A (zh) 2020-12-16
WO2020172490A1 (en) 2020-08-27
JP7637058B2 (ja) 2025-02-27
CL2021002172A1 (es) 2022-02-11
CA3129672A1 (en) 2020-08-27
CN113710281A (zh) 2021-11-26
EP3927381A1 (en) 2021-12-29

Similar Documents

Publication Publication Date Title
KR20210131370A (ko) Grn-연관 성인-발병 신경퇴화의 치료를 위한 재조합 아데노-연관 바이러스
KR20230058102A (ko) Grn 관련 성인 발병 신경변성 치료를 위한 재조합 아데노-연관 바이러스
US5756283A (en) Method for improved production of recombinant adeno-associated viruses for gene therapy
KR20210103469A (ko) 재조합 바이러스 벡터 및 이를 생산하기 위한 핵산
KR102883778B1 (ko) Ii형 점액다당류증의 치료를 위한 유전자 요법
KR20230043869A (ko) Aav 벡터를 사용한 플라코필린-2(pkp2) 유전자 요법
JP2001500497A (ja) 組換えアデノ随伴ウイルスに指図される遺伝子治療の方法
KR20210092755A (ko) 신경원성 세로이드 리포푸신증에 대한 유전자 요법
CN116113700A (zh) 用于glut1表达的腺相关病毒载体及其用途
CN115151648A (zh) 用于治疗cdkl5缺陷障碍的基因疗法
CN111718947B (zh) 用于治疗ⅲa或ⅲb型粘多糖贮积症的腺相关病毒载体及用途
US20250235554A1 (en) Methods for improving adeno-associated virus (aav) delivery
US20240033325A1 (en) Treatment of danon disease
CN116171325A (zh) 用于eEF1A2的基因疗法载体及其用途
CN117545842A (zh) SMN1和miR-23a在治疗脊髓性肌萎缩中的协同效应
KR20250102136A (ko) 중추 신경계에서의 유전자 발현을 위한 핵산 조절 요소 및 사용 방법
KR20220105158A (ko) 이식유전자 발현의 drg-특이적 감소를 위한 조성물
KR20220003553A (ko) 레트 증후군의 치료에 유용한 조성물
KR20230117731A (ko) 청력 상실의 치료를 위한 변이체 아데노-연관된 바이러스(aav) 캡시드 폴리펩티드 및 이의 유전자 치료제
KR20220007601A (ko) 치료제 투여를 위한 조성물 및 방법
KR20210132095A (ko) 크라베병의 치료에 유용한 조성물
CN115867323A (zh) 可用于治疗gm1神经节苷脂症的组成物
RU2847339C1 (ru) ВЕКТОР ГЕННОЙ ТЕРАПИИ ДЛЯ eEF1A2 И ЕГО ПРИМЕНЕНИЕ
WO2024094009A1 (zh) 用于目的基因的表达盒及其应用
KR20230023637A (ko) 크라베병의 치료에 유용한 조성물

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000